Antibodies News and Research

RSS

Two Rutgers engineers create analytical tool to accelerate the production of biologic drugs

Two Rutgers engineers specializing in the process of making drugs derived from living organisms have created an analytical tool they expect will accelerate the discovery and production of biologic drugs that are often at the cutting edge of biomedical research.

18 May 2022

Recombinant protein vaccine stands up to SARS-CoV-2 variants

A study by researchers in Texas describes a mouse model in which a subunit vaccine with alum-CpG adjuvant was tested for its ability to induce a broadly neutralizing antibody response against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 May 2022

Researchers test how three mutations work together to produce new SARS-CoV-2 variants

Like storm waves battering a ship, new versions of the SARS-CoV-2 virus have buffeted the world one after another. Recently, scientists keeping tabs on these variants noticed a trend: Many carry the same set of three mutations.

18 May 2022

Scientists report complex mutation pattern of Omicron BA.2

Recently, scientists have studied the mutation profile of SARS-CoV-2 Omicron BA.2 and analyzed its outcome based on the interaction with receptor and/or monoclonal antibodies.

18 May 2022

STOP-COVID19 trial: Brensocatib did not improve clinical status of patients with severe SARS-CoV-2 infection

Brensocatib did not improve the clinical status of patients hospitalized with severe SARS-CoV-2 infection in the double-blind randomized, placebo-controlled STOP-COVID19 multicenter clinical trial, according to research published at the ATS 2022 international conference.

18 May 2022

Study explores lipid nanoparticles against SARS-CoV-2

Researchers assessed the efficiency of lipid nanoparticles against SARS-CoV-2.

18 May 2022

Study explores neurologic complications in pediatric COVID-19 cases

Researchers evaluated neurologic complications in pediatric cases of COVID-19.

18 May 2022

Combined COVID-19 vaccination regimen found to induce more potent anti-SARS-CoV-2 antibodies

Researchers assessed the vaccine-induced humoral responses against SARS-CoV-2 post four different vaccination regimens comprising homologous and heterologous vaccine doses.

18 May 2022

Insight into sustained-release drug delivery systems

In this interview, News-Medical speaks to Thanh T. Nguyen, a project manager at Innocore Pharmaceuticals, about the mechanisms behind long-acting injectables.

From Thermo Fisher Scientific – Materials Characterization 18 May 2022

Case report: human breast milk from vaccinated woman clears persistent SARS-CoV-2 infection

A new study published in the journal Viruses aimed to report the effects of plasma infusion and then breastmilk ingestion as a therapy for persistent SARS-CoV-2 infection in a patient with a common variable immunodeficiency (CVID) phenotype.

18 May 2022

First patient dosed in Phase 1 clinical trial evaluating the safety of CF33-hNIS against solid tumors

Imugene Limited, a clinical stage immuno-oncology company, and City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced that the first patient was dosed in a Phase 1 clinical trial evaluating the safety of novel cancer-killing virus CF33-hNIS VAXINIA when used in people with advanced solid tumors.

18 May 2022

Discovery of a potent SARS-CoV-2 RBD specific human monoclonal antibody

A recent article posted to the bioRxiv* preprint server demonstrated structural underpinnings of the neutralization of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants by 002-S21F2, an extensive SARS-CoV-2 neutralizing antibody.

18 May 2022

Camelid IFNs could play important role in combating emerging zoonotic pathogens

In a recent study published in the Developmental & Comparative Immunology journal, the discovery of a novel form of mammalian interferon-Beta (IFN-β) with four cysteine residues from the dromedary camel and the five remaining members of the mammalian suborder Tylopoda is described.

17 May 2022

3rd dose of COVID mRNA vaccine expands memory and capacity of immune system to combat Omicron

Researchers from the United States have now found that the immune recall induced by a two-dose primary series of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination after an initial natural infection highly improves the longevity of the antibodies as well as induces an enhanced breadth of protection across the SARS-CoV-2 variants.

17 May 2022

Study investigates COVID-19 vaccination in pregnancy

A new study discusses the risk of COVID-19-related complications in pregnancy and the role of vaccination in reducing this risk.

17 May 2022

Researchers explore broad-based immunity against potentially pandemic-causing viruses

A new study focused on broad-spectrum immunity against viruses that harbor the potential for generating a pandemic involving humans, especially those with the potential for zoonotic spillover.

17 May 2022

Researchers explore COVID-19 vaccination in immunocompromised individuals

A new study discusses the safety and efficacy of the COVID-19 vaccination and potential strategies to optimize protection in patients with impaired immunity.

17 May 2022

Neutralization of SARS-CoV-2 by plant-made neutralizing monoclonal antibodies

In a recent study published in the journal Vaccines, researchers developed plant-based monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).

17 May 2022

A study of SARS-CoV-2-mRNA booster vaccinations in immunocompromised patients

In a recent study published in the journal Frontiers in Immunology, researchers assessed the immune responses induced by vaccination with the messenger ribonucleic acid (mRNA)-1273 vaccine or the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections among immunocompromised individuals.

17 May 2022

Broad-spectrum polymeric antivirals against SARS-CoV-2

In a recent study published in the journal Advanced Science, researchers evaluated the potential and applicability of macromolecular viral inhibitors against respiratory viral pathogens.

17 May 2022

Antibodies News and Research

Two Rutgers engineers create analytical tool to accelerate the production of biologic drugs

Recombinant protein vaccine stands up to SARS-CoV-2 variants

Researchers test how three mutations work together to produce new SARS-CoV-2 variants

Scientists report complex mutation pattern of Omicron BA.2

STOP-COVID19 trial: Brensocatib did not improve clinical status of patients with severe SARS-CoV-2 infection

Study explores lipid nanoparticles against SARS-CoV-2

Study explores neurologic complications in pediatric COVID-19 cases

Combined COVID-19 vaccination regimen found to induce more potent anti-SARS-CoV-2 antibodies

Insight into sustained-release drug delivery systems

Case report: human breast milk from vaccinated woman clears persistent SARS-CoV-2 infection

First patient dosed in Phase 1 clinical trial evaluating the safety of CF33-hNIS against solid tumors

Discovery of a potent SARS-CoV-2 RBD specific human monoclonal antibody

Camelid IFNs could play important role in combating emerging zoonotic pathogens

3rd dose of COVID mRNA vaccine expands memory and capacity of immune system to combat Omicron

Study investigates COVID-19 vaccination in pregnancy

Researchers explore broad-based immunity against potentially pandemic-causing viruses

Researchers explore COVID-19 vaccination in immunocompromised individuals

Neutralization of SARS-CoV-2 by plant-made neutralizing monoclonal antibodies

A study of SARS-CoV-2-mRNA booster vaccinations in immunocompromised patients

Broad-spectrum polymeric antivirals against SARS-CoV-2

Antibodies eBook

Deciphering the Microbiome with The Microsetta Initiative

Leveraging the power of automation to boost research

Automating research - solutions and best practices

Latest Life Science News